Ultimately, understanding the energyrequirements of everyday activities after stroke will determine whether stroke survivors are at risk of recurrent cardiovascular events. Ethics approval:
The University of Sydney Human Research Ethics Committee approved this study. All participants gave written informed consent before data collection began. Support: This research was conducted as part of a larger study Improving community ambulation which is funded by a Heart Foundation (Australia) grant (G06S2556). MA is the recipient of a scholarship provided by the University of Dammam, Kingdom of Saudi Arabia. None declared. “
“Summary of: Austin MA, et al (2010) Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised see more controlled trial. BMJ 341: c5462.
doi: 10.1136/bmj.c5462 [Prepared by Kylie Hill, CAP Editor.] Selleckchem HIF inhibitor Question: In patients with a suspected acute exacerbation of COPD, does titrated oxygen in the pre-hospital setting change mortality, length of hospital stay and blood gas measurements? Design: Cluster randomised controlled trial in which paramedics were allocated to deliver titrated or high flow oxygen. Randomisation sequence was concealed prior to allocation. Setting: Ambulance service and emergency department in Hobart, Australia. Participants: People who were: transported by ambulance to the emergency department, aged ≥35 years, breathless, and were thought to have COPD based on their acute symptoms, a patient-stated history of COPD, or a smoking history of > 10 pack-years. Randomisation
of 64 paramedics allocated 32 to the titrated oxygen Ergoloid group and 30 to the high flow oxygen group. Over the study duration, 179 and 226 patients were allocated to the titrated and high flow oxygen groups, respectively. Interventions: Patients in both groups received basic support, nebulised bronchodilators, intravenous dexamethasone and, if necessary, intravenous or intramuscular salbutamol. In addition, the intervention group received titrated oxygen via nasal prongs, with the aim of maintaining arterial oxygen saturation, measured via a pulse oximeter (SpO2) between 88% and 92%. Nebulised therapy was delivered by compressed air. The control group received high flow oxygen (8 to 10 L/min) via a non-rebreather face mask. Nebulised therapy was delivered by compressed oxygen at 6 to 8 L/min. Outcome measures: The primary outcome was pre-and in-hospital mortality. Secondary outcomes were length of hospital stay and blood gas measurements. Results: The primary outcome was captured for all enrolled patients. According to the intention to treat (ITT) analysis, mortality in the intervention and control groups was 4% (n = 7) and 9% (n = 21), respectively. The relative risk was 0.42 (95% CI 0.20 to 0.89).